Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug
The factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - April 23, 2024 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Alert Source Type: news

AI in Cancer Care: Use, Understanding, and Responsibility AI in Cancer Care: Use, Understanding, and Responsibility
Dr Maurie Markman discusses the evolving world of artificial intelligence as it affects cancer care.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA Approves New Bladder Cancer Drug FDA Approves New Bladder Cancer Drug
The first-in-class agent is approved alongside bacillus Calmette-Gu érin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Is Osimertinib Better Alone or With Chemotherapy in NSCLC? Is Osimertinib Better Alone or With Chemotherapy in NSCLC?
A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Only 4% of cancer survivors reported adhering to four key healthy lifestyle practices endorsed by the American Cancer Society.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Clinical Summary Source Type: news

PSA Detectable After Radical Prostatectomy PSA Detectable After Radical Prostatectomy
Following radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 23, 2024 Category: Internal Medicine Tags: Hematology-Oncology News Source Type: news

Hair Loss: Experts Provide Recommendations on Oral Minoxidil Hair Loss: Experts Provide Recommendations on Oral Minoxidil
The authors " identified a need for expert-based guidelines for prescribing and monitoring LDOM use in hair loss patients. "MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

Immunotherapy for Renal-Cell Carcinoma Saves Lives Immunotherapy for Renal-Cell Carcinoma Saves Lives
A 5-year randomised, placebo-controlled trial of pembrolizumab found a 38% reduction in death vs placebo.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 22, 2024 Category: Consumer Health News Tags: Hematology-Oncology Clinical Summary Source Type: news

Has Immunotherapy Found Its Place in Pancreatic Cancer? Has Immunotherapy Found Its Place in Pancreatic Cancer?
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Alectinib Approved for ALK-Positive Adjuvant NSCLC Alectinib Approved for ALK-Positive Adjuvant NSCLC
The approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Paxlovid and COVID; Breast Cancer and Lymph Node Removal
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 20, 2024 Category: Hematology Source Type: news

Salvage RT After Prostatectomy Prevails in Long-Term Comparison With Adjuvant RT
(MedPage Today) -- Adjuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage RT but added toxicity, according to long-term follow-up from a randomized trial. Freedom from distant... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 20, 2024 Category: Hematology Source Type: news

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests
(MedPage Today) -- Amid controversy and discussions about the high cost of cancer drugs, some academic medical centers profit handsomely from pharma-paid royalties on drugs developed with public funding. (Los Angeles Magazine) The FDA has mandated... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 19, 2024 Category: Hematology Source Type: news

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC
(MedPage Today) -- The FDA extended indications for alectinib (Alecensa) to include adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first such approval for an ALK inhibitor. The approval stipulates use of alectinib... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 19, 2024 Category: Hematology Source Type: news

ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data
There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2024 Category: Cancer & Oncology Tags: Neurology & Neurosurgery News Source Type: news